Australian Clinical Labs soars on robust FY results, FY26 outlook

Australian Clinical Labs

26/08/2025 03:59

** Australian Clinical Labs ACL.AX soars as much as 17.2% at A$2.93, highest since May 30

** Pathology services provider reports FY25 statutory net profit after tax of A$32.8 mln ($21.3 mln), above year-ago A$24.2 mln

** Expects FY26 total revenue of A$760 mln-A$780 mln, above FY25's A$741.3 mln

** Announces final dividend of 9 AU cents/share, taking FY dividend to 12.5 AU cents, up from year-ago 12 AU cents

** About 4 mln shares traded, ~5x the 30-day avg

** ACL last up 10.4%, trims YTD losses to 20%

($1 = A$1.5389)

 (Reporting by Anjali Singh in Bengaluru)

 ((anjali.singh2@thomsonreuters.com;))